Background: Scalp erosion in patients with deep brain stimulation (DBS) hardware is an uncommon complication that lacks a clearly defined management strategy. Previous studies have described various therapies including conservative treatment with antibiotics and surgical debridement with or without hardware removal. Objectives: The aim of this study was to review the efficacy of a hardware-sparing management strategy for the treatment of scalp erosion. Methods: Five patients with previous DBS implantation presented with scalp erosion and visible hardware exposure at the calvarial burr hole site, and underwent tension-free, vascularized, rotational scalp flap, with preservation of the leads under the pericranium. Two of the procedures were performed after an unsuccessful attempt at primary closure and 3 as a primary procedure. Each patient was followed clinically for at least 14 months postoperatively to evaluate for wound-healing and adverse effects. Results: The median duration from initial DBS hardware implantation to erosion and revision surgery was 12 months (range 1.5-62 months). Three patients were documented to have positive intraoperative cultures in spite of the absence of purulence. At the last follow-up, all patients were noted to have complete wound-healing and no evidence of infection or erosion. Conclusions: DBS scalp erosion can be managed by rotational scalp flap without hardware removal, even in cases where infection is identified.

1.
Herrington TM, Cheng JJ, Eskandar EN: Mechanisms of deep brain stimulation. J Neurophysiol 2016;115:19-38.
2.
Hamani C, Lozano AM: Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg 2006;84:248-251.
3.
Patel DM, Walker HC, Brooks R, Omar N, Ditty B, Guthrie BL: Adverse events associated with deep brain stimulation for movement disorders: analysis of 510 consecutive cases. Neurosurgery 2015;11(suppl 2):190-199.
4.
Fenoy AJ, Simpson RK, Jr: Risks of common complications in deep brain stimulation surgery: management and avoidance. J Neurosurg 2014;120:132-139.
5.
Sixel-Doring F, Trenkwalder C, Kappus C, Hellwig D: Skin complications in deep brain stimulation for Parkinson's disease: frequency, time course, and risk factors. Acta Neurochirurg 2010;152:195-200.
6.
Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM: Long-term hardware-related complications of deep brain stimulation. Neurosurgery 2002;50:1268-1274; discussion 1274-1266.
7.
Spiotta AM, Bain MD, Deogaonkar M, Boulis NM, Rezai AR, Hammert W, Lucas AR: Methods of scalp revision for deep brain stimulator hardware: case report. Neurosurgery 2008;62:249-250; discussion 250.
8.
Gomez R, Hontanilla B: The reconstructive management of hardware-related scalp erosion in deep brain stimulation for Parkinson disease. Ann Plast Surg 2014;73:291-294.
9.
Solmaz B, Tatarli N, Ceylan D, Bayri Y, Ziyal MI, Seker A: A sine-wave-shaped skin incision for inserting deep-brain stimulators. Acta Neurochirurg 2014;156:1523-1525.
10.
Park YS, Kang JH, Kim HY, Kang DW, Chang WS, Kim JP, Chang JW: A combination procedure with double C-shaped skin incision and dual-floor burr hole method to prevent skin erosion on the scalp and reduce postoperative skin complications in deep brain stimulation. Stereotact Funct Neurosurg 2011;89:178-184.
11.
Constantoyannis C, Berk C, Honey CR, Mendez I, Brownstone RM: Reducing hardware-related complications of deep brain stimulation. Can J Neurol Sci 2005;32:194-200.
12.
Bhatia S, Zhang K, Oh M, Angle C, Whiting D: Infections and hardware salvage after deep brain stimulation surgery: a single-center study and review of the literature. Stereotact Funct Neurosurg 2010;88:147-155.
13.
Temel Y, Ackermans L, Celik H, Spincemaille GH, van der Linden C, Walenkamp GH, van de Kar T, Visser-Vandewalle V: Management of hardware infections following deep brain stimulation. Acta Neurochirurg 2004;146:355-361; discussion 361.
14.
Lanotte M, Verna G, Panciani PP, Taveggia A, Zibetti M, Lopiano L, Ducati A: Management of skin erosion following deep brain stimulation. Neurosurg Rev 2009;32:111-114; discussion 114-115.
15.
Kouyialis AT, Boviatsis EJ, Ziaka DS, Sakas DE: Use of a single semilinear incision in deep brain stimulation for movement disorders. Acta Neurochirurg 2007;149:501-504; discussion 504.
16.
Yamamoto T, Katayama Y, Kobayashi K, Oshima H, Fukaya C: Dual-floor burr hole adjusted to burr-hole ring and cap for implantation of stimulation electrodes. Technical note. J Neurosurg 2003;99:783-784.
17.
Contarino MF, Bot M, Speelman JD, de Bie RM, Tijssen MA, Denys D, Bour LJ, Schuurman PR, van den Munckhof P: Postoperative displacement of deep brain stimulation electrodes related to lead-anchoring technique. Neurosurgery 2013;73:681-688; discussion 688.
18.
Favre J, Taha JM, Steel T, Burchiel KJ: Anchoring of deep brain stimulation electrodes using a microplate. Technical note. J Neurosurg 1996;85:1181-1183.
19.
Raposio E, Nordstrom RE: Tension and flap advancement in the human scalp. Ann Plast Surg 1997;39:20-23.
20.
Raposio E, Nordstrom RE, Santi PL: Undermining of the scalp: quantitative effects. Plast Reconstruct Surg 1998;101:1218-1222.
21.
Tolleson C, Stroh J, Ehrenfeld J, Neimat J, Konrad P, Phibbs F: The factors involved in deep brain stimulation infection: a large case series. Stereotact Funct Neurosurg 2014;92:227-233.
22.
Sillay KA, Larson PS, Starr PA: Deep brain stimulator hardware-related infections: incidence and management in a large series. Neurosurgery 2008;62:360-366; discussion 366-367.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.